From a chemical compounding perspective, Relafen 750 represents a unique case, primarily due to its mode of operation. The key component, naproxen, demonstrates a complex interplay with prostaglandin production, specifically targeting cyclooxygenase-2 (COX-2) enzymes. This specific inhibition tri